Guest: Robert Bissonnette, MD, FRCPC



The DELTA 1 and DELTA 2 trials examined the efficacy and safety of the topical pan-JAK inhibitor delgocitinib in patients with moderate to severe chronic hand eczema. Based on the findings, no new safety signals were observed, and nearly half of patients achieved a 75 percent improvement in HECSI scores as well as meaningful relief in itch, pain, and quality of life. Here to talk about the trials’ design and findings—as well as his own firsthand experience treating patients who were enrolled in the trials—is board-certified dermatologist Dr. Robert Bissonnette.

Ver todos los episodios